Sage Therapeutics to Participate in Leerink Investor Conference
September 22 2017 - 4:05PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that the Company will participate in the Leerink Partners
Rare Disease Roundtable on Wednesday, September 27, 2017, with a
presentation at 2:00 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed on the
investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's
website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders.
Sage has a portfolio of novel product candidates targeting critical
CNS receptor systems, GABA and NMDA. Sage's lead program,
brexanolone (SAGE-547), is in Phase 3 clinical development for
postpartum depression. Sage is developing its next generation
modulators, including SAGE-217 and SAGE-718, in various CNS
disorders. For more information, please visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170922005631/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024